EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische Studie

Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis

Troels Højsgaard Jørgensen iD, Mikko Savontaus iD, Yannick Willemen iD, Øyvind Bleie iD, Mariann Tang, Oskar Angerås iD, Matti Niemela iD, Ingibjörg J Gudmundsdóttir iD, Arif Khokhar, Ulrik Sartipy iD, Hanna Dagnegård iD, Mika Laine iD und 12 weitere

Circulation · 11.11.2025 · 152 (19) · 1326-1337

DOI: 10.1161/circulationaha.125.076678 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 11.11.2025. Verfasst von Troels Højsgaard Jørgensen und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology (T.H.J., Y.W., A.K., O.D.B.), Rigshospitalet, Copenhagen University Hospital, Denmark. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Aortic Valve, Heart Valve Diseases. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Abbott, Boston Scientific, Edwards Lifesciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is increasingly performed in younger, low surgical risk patients. The NOTION-2 study (The Nordic Aortic Valve Intervention) reports midterm outcomes in low-risk patients age 60 to 75 years with severe tricuspid or bicuspid aortic stenosis undergoing TAVR or surgical valve replacement. METHODS: A total of 370 patients (mean age, 71.1 years; mean Society of Thoracic Surgeons Predicted Risk of Mortality, 1.2%) were enrolled and randomized 1:1 to TAVR or surgery. This follow-up study reports clinical and echocardiographic outcomes up to 3 years of follow-up. RESULTS: At 3 years, the primary composite end point (death, stroke, or procedure-, valve-, or heart failure–related hospitalization) occurred in 16.1% of patients with TAVR versus 12.6% in surgical patients (hazard ratio, 1.3; 95% CI, 0.8–2.2%; I=0.4). Among patients with tricuspid aortic stenosis, rates were similar (14.5% versus 14.4%), whereas patients with bicuspid aortic stenosis had a statistically nonsignificant higher risk with TAVR (20.4% versus 7.8%; hazard ratio, 2.9; 95% CI, 0.9–9.0). The risk of moderate or greater structural valve deterioration at 3 years was 4.5% and 5.2% for transcatheter and surgical aortic bioprostheses, respectively (hazard ratio, 1.2; 95% CI, 0.4–3.1). Bioprosthetic valve failure rates were also comparable: 1.6% in the TAVR group and 2.9% in the surgical group. CONCLUSIONS: For patients age 60 to 75 years with severe aortic stenosis who are at low surgical risk, 3-year clinical outcomes are similar between TAVR and surgery. Both procedures are associated with low rates of structural valve deterioration and need for reintervention. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02825134.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisAortic ValveHeart Valve DiseasesHeart Valve Prosthesis ImplantationHumansAgedMaleFemaleFollow-Up StudiesMiddle AgedBicuspid Aortic Valve DiseaseTreatment OutcomeRisk FactorsAge Factors

Stichwörter der Autor:innen

aortic stenosislow surgical risksurgical aortic valve replacementtranscatheter aortic valve replacementyounger patients

Autor:innen und Institutionen

  • Department of Cardiology (T.H.J., Y.W., A.K., O.D.B.), Rigshospitalet, Copenhagen University Hospital, Denmark.
  • Department of Cardiology, Haukeland University Hospital, Bergen, Norway (Ø.B., R.H.).
  • Department of Cardiology, Medical Research Center, Oulu University Hospital, Finland (M.N., J.P.).
  • Department of Cardiology, Landspitali, Reykjavík, Iceland (I.J.G.).
  • Department of Cardiothoracic Surgery (U.S.), Karolinska University Hospital, Stockholm, Sweden.
  • Department of Cardiothoracic Surgery, Odense University Hospital, Denmark (H.D.).

ORCID-Profile: Troels Højsgaard Jørgensen, Mikko Savontaus, Yannick Willemen, Øyvind Bleie, Oskar Angerås, Matti Niemela, Ingibjörg J Gudmundsdóttir, Ulrik Sartipy, Hanna Dagnegård, Mika Laine, Andreas Rück, Jarkko Piuhola, Evald H Christiansen, Markus Malmberg, Rune Haaverstad, Ole De Backer

Förderung

  • Abbott
  • Boston Scientific
  • Edwards Lifesciences

Zitieren

APA

Jørgensen, T. H., Savontaus, M., Willemen, Y., Bleie, Ø., Tang, M., Angerås, O., Niemela, M., Gudmundsdóttir, I. J., Khokhar, A., Sartipy, U., Dagnegård, H., Laine, M., Rück, A., Piuhola, J., Petursson, P., Christiansen, E. H., Malmberg, M., Olsen, P. S., Haaverstad, R., …, & NOTION-2 Investigators (2025). Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis. Circulation, 152(19), 1326-1337. https://doi.org/10.1161/circulationaha.125.076678

Vancouver

Jørgensen TH, Savontaus M, Willemen Y, Bleie Ø, Tang M, Angerås O, et al. Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis. Circulation. 2025;152(19):1326-1337. doi:10.1161/circulationaha.125.076678

BibTeX
@article{Jrgensen2025,
  author = {Jørgensen, Troels Højsgaard and Savontaus, Mikko and Willemen, Yannick and Bleie, Øyvind and Tang, Mariann and Angerås, Oskar and Niemela, Matti and Gudmundsdóttir, Ingibjörg J and Khokhar, Arif and Sartipy, Ulrik and Dagnegård, Hanna and Laine, Mika and Rück, Andreas and Piuhola, Jarkko and Petursson, Petur and Christiansen, Evald H and Malmberg, Markus and Olsen, Peter Skov and Haaverstad, Rune and Prendergast, Bernard and Sondergaard, Lars and Hørsted Thyregod, Hans Gustav and De Backer, Ole and NOTION-2 Investigators, NOTION-2 Investigators},
  title = {Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis},
  journal = {Circulation},
  year = {2025},
  volume = {152},
  number = {19},
  pages = {1326--1337},
  doi = {10.1161/circulationaha.125.076678}
}
Kostenlos starten →